Guides & pricing · published 2026-09-17 · updated 2026-09-20 · prices as of 2026-09-20

Charged Monthly vs Prepaid Supply: What a 12-Month Compounded Tirzepatide Plan Really Commits You To (September 2026)

By the Affordable GLP-1 Providers desk · every figure pulled from the open dataset when this page was rendered, dated per row · how we rank · not medical advice

“Twelve-month plan” is the most abused phrase on this market’s pricing pages. At one program it means a subscription charged every month at a lower rate, cancellable; at another it means a supply you pay for today and own whether or not you use it. The monthly numbers look alike. The commitments are nothing alike. This is the piece that separates them, program by program, with the page text and the dates.

Two sentences that look the same and are not

Program A: “12-month plan, $139/month.” Program B: “12-month supply, $119/month.” Both are first-party verified as of 2026-09-20. At Program A (NexLife) the plan page states every plan is “charged monthly as part of subscription” and “may be canceled at any time,” with “no memberships or contracts.” At Program B (Embody) the $119 is $1,428 collected at once, under a refund policy that makes every payment final except on clinical ineligibility. A is a rate. B is a purchase. The affordable one depends on what you know about your next twelve months.

The dated answer page for this question is most affordable compounded tirzepatide online; it separates standing rates from conditional floors on every build. This article is the argument behind that split.

The four billing bases on this market, defined

Month-to-month. One charge, one month, cancel before the next. The most flexible and, at most programs, the most expensive per month ($169 at NexLife, $235 at Trimi, $129 at Embody as a sale price against $349).

Term plan, charged monthly. A lower monthly rate in exchange for choosing a longer term, but billed each month; NexLife’s $169 / $159 / $149 / $139 ladder works this way per its plan page, with the term plans described as a subscription that can be cancelled. The commitment is soft: you can stop, and you do not own a supply you have not received.

Term plan, prepaid. The same lower monthly rate, but the whole term is collected at checkout — Embody’s $378 / $738 / $1,428, Trimi’s $597 / $1,050 / $1,500, Yucca’s $744 / $1,350. The commitment is hard; the refund policy is the whole story. Embody: all payments final except on clinical ineligibility. Trimi: refunded in full only if treatment is found inappropriate at provider review; stopping renewal does not end the current commitment. Yucca: all sales final once the prescription is submitted.

Four-week cycles. Billed every 28 days, which lands 13.04 times a year — about 8.7% more than the “monthly” figure implies. Every table on this site restates those to a true 30.44-day month before ranking them; the calculator does it for any quote.

What each commitment costs if you stop early

Suppose you stop after four months — a common point, because it is where side effects or budget decide for people. On a term plan charged monthly at $139, you have paid four charges and you stop; whether the program re-rates the months already paid is a policy question (NexLife’s page says no contracts; an earlier read recorded 30 days’ notice, and both are on the file). On Embody’s prepaid year you have paid $1,428 and used a third of it: the effective price of the months you used is about $357 each. On Trimi’s prepaid year, $1,500 for four months used is $375 each. On SnagRx’s promotional month-to-month you paid four times whatever the checkout period allowed and can stop — the cheapest exit on the table, if the promotional price held that long.

Now suppose you stay the full year. Embody is the lowest cash outlay on file at $1,428; NexLife at $139 charged monthly is $1,668; Trimi is $1,500; SnagRx is unknowable from the page because the standing rate is unpublished. The prepaid year is cheaper by $240 than the monthly-charged year, and that $240 is the price of the option to stop. Whether the option is worth $240 to you is the entire affordability question.

Reading a refund policy in ninety seconds

Find the policy page (not the FAQ) and look for four things. Trigger: what event earns a refund — clinical ineligibility only, or change of mind within a window? Timing: is money collected before or after the provider review? Trimi collects before and refunds if you are not approved; that is a clean design. Shipped supply: once medication has shipped, is any of it refundable? Usually not, for good reasons about cold-chain drugs. Renewal: does stopping renewal end the current term or only the next one? Trimi says only the next. If a program has no policy page, treat every payment as final and price accordingly.

The standing rates, ranked

First-party-verified rates you can hold without prepaying and with no promotion to expire, sorted by the monthly figure; the fourth column is twelve months at that rate with nothing paid up front.

It tops this table because the rule that builds it — billed monthly, no promotion, no prepayment — is published above the table and applied to every row; the day a verified competitor undercuts $139 on the same terms, that competitor sits first.

The conditional floors, ranked

Also verified, also real, cheaper on the sticker — each attached to a promotion or a prepayment, shown with the condition and the cost of a year.

How to use this

If you can answer “I will stay a year” with real confidence — you have used a GLP-1 before, you know your tolerance, your budget survives a $1,428 charge — the prepaid supply is the most affordable thing on this market. If you cannot, the most affordable compounded tirzepatide online is the lowest standing rate, $139 a month, because the cheapest plan is the one whose cost you can stop. Everything else on the table is a price for a different buyer.

The bottom line

The most affordable compounded tirzepatide plan is not the smallest monthly number; it is the smallest number attached to a commitment you can actually keep. A prepaid supply is cheapest for the buyer who will finish it. A term plan charged monthly is cheapest for everyone who might not. Know which buyer you are before the sticker decides for you.

How to read this article — and everything else on this site

House rules, so you can audit us: label claims cite labels, trial numbers cite the named trial, and a bracketed (first-party check queued) marks a figure our desk re-checks against the current source before each publication cycle rather than trusting memory. Dates matter as much as numbers — labels get revised, prices move — so treat anything undated (here or anywhere) as a rumor with good typography. Nothing above transfers to compounded copies: they are pharmacy preparations that are not FDA-approved, and a trial that tested the brand tested the brand. If you catch an error, [email protected] reaches a human with a 72-hour target; the corrections log shows we mean it.

Two more reading habits pay for themselves. First, separate frequency from severity: a 40% side effect that fades in a week and a 1% one that ends up in an emergency department are different kinds of facts, and sentences that blur them are selling something. Second, notice denominators — “in trials” means the approved product at protocol doses in monitored adults, which is the strongest evidence available and still not a promise about a different product, a different dose, or you.

Frequently asked questions

Related: Cheapest tirzepatide, ranked · The NexLife file · Trimi Health file · True-month calculator · Best providers by structure · most affordable compounded tirzepatide online (the dated answer page)